Alzheon hits an­oth­er dead end fund­ing its Alzheimer's pro­gram, pulls sec­ond IPO at­tempt

If at first you don’t suc­ceed… maybe it wasn’t such a good idea.

Alzheon has learned that the hard way as it with­draws its …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA